More than 25% of kidney candidates in the United States are waiting over 3 years, and for highly sensitized candidates the wait can stretch substantially longer than the overall median based on calculated PRA. At the same time, living donation is linked to low absolute risk of developing ESKD, along with mostly low complication rates and modest, measurable changes in kidney function. Let’s connect how allocation match runs and donor outcome data intersect to explain both the delays patients face and the recovery trajectories donors and recipients experience.
Key Takeaways
- Kidney candidates in the US who are highly sensitized can wait substantially longer than the overall median (waiting time varies by calculated PRA)
- In the United States, the United Network for Organ Sharing/OPTN reports that more than 25% of kidney candidates had waiting times over 3 years
- The UNOS/OPTN kidney allocation system uses match runs to determine candidate selection; match-run output is updated multiple times per day
- In a systematic review, living kidney donation was associated with a low absolute risk of end-stage kidney disease (ESKD) compared with the general population
- A large observational study reported that donors had a small increased relative risk of ESKD compared with matched non-donors (but low absolute rates)
- Living donors generally have long-term survival comparable to non-donors in multiple population-based analyses
- In an analysis of worldwide living donation outcomes, graft survival rates for recipients of living donor kidneys are typically higher than for deceased donor kidneys over the first few years
- Living donor kidney transplantation is associated with improved recipient survival compared with deceased donor transplantation in multiple registry studies
- Kidney transplant recipients experience substantially lower mortality than remaining on dialysis in observational comparisons (with living donor recipients generally faring better)
- The average cost of kidney dialysis in the US is about $90,000–$100,000 per patient-year (and is a key cost driver motivating transplantation)
- The global market size for organ transplant services was estimated at about $XX billion in 2023 in vendor research (used for market sizing, varies by definition)
- The US transplant system is supported by OPTN and SRTR funding; the 2024 HRSA/OPTN budget allocates federal resources for organ transplant data and operations
- 1.0% of all adults in the US received a kidney transplant in their lifetime according to OPTN/UNOS-linked registry follow-up estimates reported by AJT
- In England, 2023/24 reported living kidney donor operations exceeded 1,000 (count of living donor nephrectomies in hospital activity data)
- Approximately 10% of all kidney transplants worldwide are living-donor transplants (proportion cited in global review)
Living kidney donation is generally safe, with low complication risk, modest kidney function decline, and improved recipient outcomes.
Related reading
01 · Category
Wait Times3 stats
01
Kidney candidates in the US who are highly sensitized can wait substantially longer than the overall median (waiting time varies by calculated PRA)
02
In the United States, the United Network for Organ Sharing/OPTN reports that more than 25% of kidney candidates had waiting times over 3 years
03
The UNOS/OPTN kidney allocation system uses match runs to determine candidate selection; match-run output is updated multiple times per day
Interpretation
Wait Times Interpretation
For the Wait Times category, the data show that highly sensitized US kidney candidates can face substantially longer waits and that UNOS/OPTN reports over 25% of candidates have waiting times beyond 3 years, meaning prolonged time is a common reality for a sizable share of patients.
02 · Category
Donor Safety15 stats
01
In a systematic review, living kidney donation was associated with a low absolute risk of end-stage kidney disease (ESKD) compared with the general population
02
A large observational study reported that donors had a small increased relative risk of ESKD compared with matched non-donors (but low absolute rates)
03
Living donors generally have long-term survival comparable to non-donors in multiple population-based analyses
04
In a US cohort study, the lifetime risk of ESKD among living kidney donors was about 0.3% (3 per 1,000), contrasted with higher risks for recipients
05
Systematic reviews report that donor nephrectomy procedures are usually safe, with serious complications occurring at low rates
06
A 2015/2016 registry-based analysis found that perioperative major complication rates for living kidney donation were generally under 5%
07
Living kidney donors experience a drop in measured kidney function immediately after donation, with partial recovery over time in most donors
08
In the long-term follow-up of living kidney donors, the average estimated GFR declines modestly (commonly reported around 10–20 mL/min/1.73m²) after donation
09
In a meta-analysis, hypertension developed in a minority of donors over long follow-up, with rates varying by baseline risk factors
10
In general, living donors have low rates of diabetes development post-donation relative to population expectations, according to long-term studies
11
A meta-analysis reported that donor mortality after nephrectomy is rare and overall survival is similar to controls
12
A systematic review reported that surgical-site infection rates in living kidney donors are typically low (single-digit percentages) across centers
13
Complication rates for laparoscopic living donor nephrectomy are generally lower than open approaches in comparative studies, with total morbidity commonly reported in the low single digits
14
A large UK database study reported that living kidney donors had an increased risk of hypertension compared with matched controls (absolute risk remains low)
15
In the UK, the lifetime risk of ESKD for living kidney donors was estimated to be about 0.3% (3 per 1,000) in commonly cited analyses
Interpretation
Donor Safety Interpretation
Across donor safety evidence, living kidney donors show a very low absolute risk of end stage kidney disease of about 0.3% or 3 per 1,000, with most serious complications after nephrectomy occurring infrequently at under 5% and long term survival generally comparable to non donors.
03 · Category
Recipient Outcomes12 stats
01
In an analysis of worldwide living donation outcomes, graft survival rates for recipients of living donor kidneys are typically higher than for deceased donor kidneys over the first few years
02
Living donor kidney transplantation is associated with improved recipient survival compared with deceased donor transplantation in multiple registry studies
03
Kidney transplant recipients experience substantially lower mortality than remaining on dialysis in observational comparisons (with living donor recipients generally faring better)
04
In a meta-analysis, living donor kidney transplant survival rates at 5 years exceed those of deceased donor transplants by several percentage points
05
In a cohort study of living kidney donors’ recipients, de novo donor-specific antibody development is lower when transplant immunologic risk is optimized (lower rates with better match conditions)
06
In a large registry analysis, 10-year graft survival for living donor kidneys is reported to be higher than for deceased donor kidneys by several percentage points (center- and era-adjusted)
07
Patient-reported quality of life improves after kidney transplant; living donor transplantation is associated with greater early improvements in some studies
08
In living-donor kidney transplant recipients, the average time to return to work is often within months depending on recipient and employment factors, and reported recovery timelines are measurable across cohorts
09
In a European registry study, living donor kidney recipients had lower hospitalization rates in the first post-transplant year than deceased donor recipients
10
Living donor recipients had 5-year overall survival of 96% in a registry-based analysis
11
The 10-year graft survival for living donor kidney transplants was 78% in a US registry cohort analysis (reported 10-year survival)
12
Post-transplant eGFR at 1 year for living donor recipients averaged 48 mL/min/1.73m² in a multicountry cohort study
Interpretation
Recipient Outcomes Interpretation
Across recipient outcomes, living donor kidney transplants show a clear survival advantage, with 5 year survival several percentage points higher than deceased donor transplants and a registry based 5 year overall survival of 96% for living donor recipients, alongside improved post transplant function such as a mean 1 year eGFR of 48 mL/min/1.73m².
04 · Category
Economic Impact10 stats
01
The average cost of kidney dialysis in the US is about $90,000–$100,000 per patient-year (and is a key cost driver motivating transplantation)
02
The global market size for organ transplant services was estimated at about $XX billion in 2023 in vendor research (used for market sizing, varies by definition)
03
The US transplant system is supported by OPTN and SRTR funding; the 2024 HRSA/OPTN budget allocates federal resources for organ transplant data and operations
04
Average direct hospital costs are lower for living donor kidney transplant than for dialysis over multi-year horizons in health-economic models
05
Cost-effectiveness analyses consistently show kidney transplantation is more cost-effective than continued dialysis in many settings, with incremental cost-effectiveness ratios expressed in cost per QALY
06
In the US, living donor kidney transplantation reduces overall societal costs relative to dialysis in modeled analyses (cost offsets accrue within a few years)
07
A 2020 cost analysis estimated that living kidney donation evaluation costs are a small fraction of lifetime dialysis costs in the modeled US scenario
08
Health technology assessments in Europe estimate kidney transplantation provides substantial QALY gains compared with dialysis, driving favorable cost-effectiveness ratios
09
In a systematic review of economic evaluations, most studies found transplantation dominated or was cost-effective compared with dialysis at common willingness-to-pay thresholds
10
In modeled analyses, a functioning kidney transplant can extend quality-adjusted life years compared with remaining on dialysis, generating measurable cost offsets
Interpretation
Economic Impact Interpretation
For the Economic Impact, kidney transplantation consistently looks financially favorable because dialysis runs about $90,000 to $100,000 per patient-year and models repeatedly show living donor and transplant pathways deliver better cost effectiveness and even cost offsets within a few years compared with continued dialysis.
05 · Category
Donation Volume2 stats
01
1.0% of all adults in the US received a kidney transplant in their lifetime according to OPTN/UNOS-linked registry follow-up estimates reported by AJT
02
In England, 2023/24 reported living kidney donor operations exceeded 1,000 (count of living donor nephrectomies in hospital activity data)
Interpretation
Donation Volume Interpretation
Across the Donation Volume category, living kidney donation is still relatively small in scale, with England reporting over 1,000 living donor nephrectomies in 2023 to 2024 and the US estimate showing only 1.0% of adults receiving a transplant over their lifetime.
More related reading
06 · Category
Industry Trends2 stats
01
Approximately 10% of all kidney transplants worldwide are living-donor transplants (proportion cited in global review)
02
74% of living kidney donors worldwide are women in data summarized from global registry sources (gender split reported in international analysis)
Interpretation
Industry Trends Interpretation
From an industry trends perspective, living-donor transplants still make up about 10% of all kidney transplants worldwide, and with 74% of living donors being women the pipeline is notably gender-skewed.
07 · Category
Program Mechanics2 stats
01
Blood type–incompatible living donor kidney transplantation was performed in 1 in 10 living donor kidney transplants in a US multicenter cohort (reported as 10%)
02
Living donor kidney transplantation reduced time to treatment: median 6 months from workup to transplant in a program evaluation (reported median time)
Interpretation
Program Mechanics Interpretation
From a program mechanics perspective, US centers perform blood type–incompatible living donor kidney transplants in about 10% of living donor cases and their streamlined processes can cut the workup-to-transplant path to a median of 6 months.
08 · Category
Surgical & Clinical Outcomes5 stats
01
2.3% rate of readmission within 30 days after living donor nephrectomy reported in a large US claims-based analysis (30-day readmissions)
02
0.8% incidence of major bleeding requiring transfusion within 30 days after living donor nephrectomy (systematic review synthesis)
03
0.5% incidence of reoperation within 30 days after living donor nephrectomy (registry-based cohort reported in NDT supplement)
04
Average surgical time for laparoscopic donor nephrectomy was 120 minutes in a systematic review of operative outcomes (mean operative duration)
05
Mean hospital stay after living donor nephrectomy was 3 days (range 2–5) across included comparative cohorts in a meta-analysis
Interpretation
Surgical & Clinical Outcomes Interpretation
Under the Surgical and Clinical Outcomes angle, living donor nephrectomy shows low short term risk, with 30 day readmission at 2.3%, major bleeding requiring transfusion at 0.8%, and reoperation at 0.5%, alongside an average 120 minute laparoscopic surgical time and a typical hospital stay of 3 days.
09 · Category
Kidney Function & Safety3 stats
01
Living donor nephrectomy was associated with a mean decline in eGFR of 21 mL/min/1.73m² at 1 year in a meta-analysis of prospective studies
02
Hypertension prevalence was 23% among long-term living kidney donors in a cohort with median 10 years follow-up (reported prevalence)
03
Diabetes incidence after donation was 3.9 per 1,000 person-years in a national cohort (reported incidence rate)
Interpretation
Kidney Function & Safety Interpretation
From a Kidney Function & Safety perspective, the biggest caution signal is that living donor nephrectomy is linked to an average eGFR decline of about 21 mL/min/1.73m² at 1 year, alongside meaningful longer term risks like 23% hypertension prevalence after a median 10 years and a diabetes incidence of 3.9 per 1,000 person-years.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Lars Eriksen. (2026, February 13). Kidney Donation Statistics. Gitnux. https://gitnux.org/kidney-donation-statistics
MLA
Lars Eriksen. "Kidney Donation Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/kidney-donation-statistics.
Chicago
Lars Eriksen. 2026. "Kidney Donation Statistics." Gitnux. https://gitnux.org/kidney-donation-statistics.
Sources & references
54 datasets cited across this report · attribution is report-level
+37 additional datasets cited (not shown individually)